The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Texas MPN Workshop 2022 | The importance of genomic testing in MPNs and other myeloid malignancies
Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, shares some insights into the importance of genomic testing in myeloproliferative neoplasms (MPNs) and other myeloid malignancies, and further discusses the value of testing patients for clonal hematopoiesis of indeterminate potential (CHIP). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Aptose Biosciences – employment and equity
Gilead – data safety monitoring committees chair
Epizyme – data safety monitoring committee chair
BMS – ad hoc advisory board honoraria, research funding
Takeda – research funding
